Gaucher Disease Type 1 Pipeline Analysis Report 2026

Report Coverage

The Gaucher Disease Type 1 Pipeline Analysis Report by Expert Market Research gives comprehensive insights into Gaucher disease type 1 therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Gaucher disease type 1. The Gaucher disease type 1 report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Gaucher disease type 1 pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Gaucher disease type 1 treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Gaucher disease type 1.

Read more about this report - Request a Free Sample

Gaucher Disease Type 1 Pipeline Outlook

Gaucher disease type 1 is a hereditary lysosomal storage disorder caused by a deficiency of the enzyme glucocerebrosidase. This deficiency leads to the accumulation of glucocerebroside in macrophages, resulting in enlarged liver and spleen, anemia, bone pain, and skeletal abnormalities. The condition primarily affects adolescents and adults, with progressive multi-organ involvement that can become life-threatening if untreated.

Gaucher disease type 1 treatments focus on enzyme replacement therapy using recombinant human glucocerebrosidase, which significantly improves organ function, alleviates hematological symptoms, and enhances patients' quality of life. In May 2025, Velaglucerase beta for injection (CAN103) received NMPA approval. Developed through Phase I/II trials led by PUMCH, this innovative enzyme replacement therapy provides long-term treatment for adolescents aged 12 years and older and adults, demonstrating significant efficacy, favorable safety, and sustained clinical benefits.

Gaucher Disease Type 1 Epidemiology

The data on Gaucher disease type 1 highlight its epidemiological significance and impact on drug development. According to Daniela Anahí Méndez-Cobián et al., 2024, Gaucher disease is the most common lysosomal storage disorder, with an incidence of 1 case per 40,000–60,000 births globally and 0.125% of births among the Ashkenazi Jewish population. According to Gaucher disease type 1 epidemiology forecast by Expert Market Research, over 90% of patients in North America and Europe have type 1, presenting primarily with splenomegaly, hepatomegaly, and blood and bone abnormalities. As per Aya Narita et al., 2024, Japan has a prevalence of 1 in 330,000, affecting approximately 211 patients. These data underscore the need for continued drug development.

Gaucher Disease Type 1 – Pipeline Therapeutic Assessment

Gaucher Disease Type 1 Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II with 50%, covers a major share of the total Gaucher disease type 1 clinical trials, reflecting strong ongoing clinical development and potential near-future therapeutic advancements. Phase I contributes 33%, highlighting promising early-stage candidates. Phase III represents 11%, indicating progress toward late-stage approval. These active phases collectively support growth and expansion in the Gaucher disease type 1 treatment landscape.

Gaucher Disease Type 1 Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the Gaucher disease type 1 pipeline analysis include small molecules, monoclonal antibodies, peptides, proteins, and vaccines. The Gaucher disease type 1 report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Gaucher disease type 1. Enzyme replacement therapies and substrate reduction therapies are the main drug classes under investigation for Gaucher Disease Type 1. For instance, eliglustat, an oral substrate reduction therapy, is being studied alone or in combination with imiglucerase, an intravenous enzyme replacement therapy, to evaluate safety and efficacy in pediatric patients. These approaches aim to reduce fat accumulation in organs and improve hematological and bone-related symptoms.

Gaucher Disease Type 1 Clinical Trials – Key Players

The EMR report for the Gaucher disease type 1 pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Gaucher disease type 1 therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Gaucher disease type 1 clinical trials:

• Spur Therapeutics
• Prevail Therapeutics
• Lingyi Biotech Co., Ltd.
• Genzyme
• Sanofi
• Eli Lilly and Company
• ISU Abxis Co., Ltd.
• Shire
• Actelion
• Amicus Therapeutics
• Takeda
• Yuhan Corporation

Gaucher Disease Type 1 – Emerging Drugs Profile

Key Questions Answered in the Gaucher Disease Type 1 Pipeline Insight Report

• Which companies/institutions are leading the Gaucher disease type 1 drug development?
• Which company is leading the Gaucher disease type 1 pipeline development activities?
• What is the current Gaucher disease type 1 commercial assessment?
• What are the opportunities and challenges present in the Gaucher disease type 1 pipeline landscape?
• What is the efficacy and safety profile of Gaucher disease type 1 pipeline drugs?
• Which company is conducting major trials for Gaucher disease type 1 drugs?
• Which companies/institutions are involved in Gaucher disease type 1 collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in Gaucher disease type 1?

Reasons To Buy This Report

The Gaucher Disease Type 1 Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for Gaucher disease type 1. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Gaucher disease type 1 collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Gaucher Disease Type 1 Epidemiology Forecast

Gaucher’s Disease Treatment Market